One of the major breakthroughs in breast cancer treatment was the development of recombinant humanized monoclonal antibodies (mAbs), such as trastuzumab (anti-human epidermal growth factor receptor (HER2) antibody) and bevacizumab (anti-vascular endothelial growth factor (VEGF) antibody). This evidence concerns the gene VEGFA and breast cancer.